Pfizer stops OTC Lipitor trial

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Pfizer will not be manufacturing an over-the-counter version of atorvastatin (Lipitor) after the company terminated its clinical trial program, Bloomberg reports. Since losing patent protection in 2011, sales of atorvastatin have decreased from more than $10 billion per year to $2.06 billion in 2014.